title: Reduced incidence of severe infection after heart transplantation with low-intensity immunosuppression.
abstract: Despite advances in immunosuppressive therapy and prolonged graft and patient survival, infection after heart transplantation remains problematic. From January 1987 through June 1989, 104 heart transplantations were performed in 100 patients. Immunosuppression induction was by antilymphocyte globulin for 7 days, with oral cyclosporine introduced on stabilization of kidney function (day 3). Steroid therapy was rapidly tapered, and azathioprine was added only in cases of positive donor crossmatch or steroid-resistant rejection. No reverse isolation was used. Twenty-two deaths occurred, one from sepsis. Actuarial survival at 6 months, at 1 year, and at 2 years was 85% +/- 4%, 81% +/- 3%, and 75% +/- 4%, respectively. Fifty-four patients had 81 infections, of which 21 were bacterial; 83% of these episodes were treated. Sixty infections were opportunistic (85% viral), and only 23% necessitated treatment. Actuarial infection-free rates (all types necessitating treatment) at 1 month, at 6 months, and at 2 years were 83% +/- 4%, 75% +/- 5%, and 75% +/- 5%, respectively. Of the 100 transplant recipients, 66% were treated with azathioprine; 47 patients (69%) had an infection, whereas only seven (19%) of the patients not receiving azathioprine became infected (p less than 0.00001). Rejection was noted in 66% of patients, with a median time to the first episode of 4 weeks. A low-intensity immunosuppressive regimen has resulted in fewer serious infections, with acceptable graft loss from rejection. Increased infection surveillance is required for the first 30 days postoperatively and after treatment of rejection episodes.
authors.affiliation: University Hospital, London, Ontario, Canada.
authors.forename: K R
authors.initials: KR
authors.lastname: Reid
authors.forename: A H
authors.initials: AH
authors.lastname: Menkis
authors.forename: R J
authors.initials: RJ
authors.lastname: Novick
authors.forename: P W
authors.initials: PW
authors.lastname: Pflugfelder
authors.forename: W J
authors.initials: WJ
authors.lastname: Kostuk
authors.forename: J
authors.initials: J
authors.lastname: Reid
authors.forename: J L
authors.initials: JL
authors.lastname: Whitby
authors.forename: A M
authors.initials: AM
authors.lastname: Powell
authors.forename: F N
authors.initials: FN
authors.lastname: McKenzie
mesh_terms: D000206:Actuarial Analysis; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001424:Bacterial Infections / Q000453:epidemiology* / Q000517:prevention & control; D016572:Cyclosporine / Q000627:therapeutic use; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D015994:Incidence; D009894:Opportunistic Infections / Q000453:epidemiology*; D011183:Postoperative Complications / Q000453:epidemiology*; D014777:Virus Diseases / Q000453:epidemiology* / Q000517:prevention & control
chemical_list: D000961:Antilymphocyte Serum; D016572:Cyclosporine; D001379:Azathioprine